Cui, Yimin

Targeting integrin pathways: mechanisms and advances in therapy

Pang, X., He, X., Qiu, Z., Zhang, H., Xie, R., Liu, Z., Gu, Y., Zhao, N., Xiang, Q., & Cui, Y. (2023) · Signal Transduction and Targeted Therapy

Cell Adhesion Molecules ResearchBiochemical and Structural Characterization

Cited by 1,275

Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis

Li, M., Zhou, Y., Chen, C., Yang, T., Zhou, S., Chen, S., Wu, Y., & Cui, Y. (2019) · Orphanet Journal of Rare Diseases

Tuberous Sclerosis Complex ResearchPI3K/AKT/mTOR signaling in cancer

Cited by 83

Application of Physiologically Based Pharmacokinetic Modeling of Novel Drugs Approved by the U.S. Food and Drug Administration

Sun, Z., Zhao, N., Zhao, X., Wang, Z., Liu, Z., & Cui, Y. (2024) · European Journal of Pharmaceutical Sciences

Pharmaceutical studies and practicesStatistical Methods in Clinical Trials

Cited by 65

Effects of vitamin D receptor, cytochrome P450 3A, and cytochrome P450 oxidoreductase genetic polymorphisms on the pharmacokinetics of remimazolam in healthy Chinese volunteers

Hu, K., Xiang, Q., Wang, Z., Sheng, X., Li, L., Liang, Y., Zhao, X., Ye, X., & Cui, Y. (2021) · Clinical Pharmacology in Drug Development

Pharmacogenetics and Drug MetabolismAnesthesia and Sedative Agents

Cited by 17